CDIO (Cardio Diagnostics Holdings) Cyclically Adjusted PS Ratio: (As of Jul. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CDIO Cardio Diagnostics Holdings Inc CDIO
49 GF Score
Price $1.57
GF Value $2.77
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Cardio Diagnostics Holdings Cyclically Adjusted PS Ratio?

Cardio Diagnostics Holdings does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Cardio Diagnostics Holdings  (NAS:CDIO) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Cardio Diagnostics Holdings Cyclically Adjusted PS Ratio Related Terms


Cardio Diagnostics Holdings Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Cardio Diagnostics Holdings's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardio Diagnostics Holdings Cyclically Adjusted PS Ratio Chart

Cardio Diagnostics Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Cardio Diagnostics Holdings Quarterly Data
Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CDIO vs ERNA, LABT, JAGX: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Cardio Diagnostics Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardio Diagnostics Holdings Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardio Diagnostics Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Cardio Diagnostics Holdings's Cyclically Adjusted PS Ratio falls into.


CDIO
49GF Score
Cardio Diagnostics Holdings Inc CDIO
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cardio Diagnostics Holdings Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Cardio Diagnostics Holdings does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Is Cardio Diagnostics Holdings (CDIO) Overvalued in 2026?

Based on GuruFocus' analysis, Cardio Diagnostics Holdings stock appears to be undervalued. The current stock price of $1.57 is trading 43.2% below its estimated GF Value™ of $2.77. GuruFocus considers Cardio Diagnostics Holdings to be Possible Value Trap.

Key valuation signals for CDIO:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $2.77 vs. price of $1.57 (43.2% below fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the CDIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cardio Diagnostics Holdings Business Description

Address 311 West Superior Street, Suite 444, Chicago, IL, USA, 60654
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
49GF Score

Get the complete analysis for CDIO

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.57
Price
$2.77
GF Value